[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334704-105":59,"doc-detail-334704-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","previous-cancers-in-women-diagnosed-with-premature-ovarian-insufficiency-a-nationwide-population-based-casecontrol-study","Previous cancers in women diagnosed with premature ovarian insufficiency - A nationwide population-based case–control study","","To investigate prior cancer diagnoses among women with premature ovarian insufficiency (POI) and compare their frequency with the general population, this nationwide case–control study used Finnish registry data from 1953 to 2018. Women receiving hormone replacement therapy reimbursement for ovarian insufficiency before age 40 (n=5221) were matched with age- and municipality-based controls (n=20822). Prior cancer history was the main exposure. Odds ratios quantified associations overall and by cancer type, age at cancer diagnosis, and time interval between cancer and POI. Risk was highest in the first 2 years and remained elevated beyond 10 years.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/previous-cancers-in-women-diagnosed-with-premature-ovarian-insufficiency-a-nationwide-population-based-casecontrol-study/334704/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/previous-cancers-in-women-diagnosed-with-premature-ovarian-insufficiency-a-nationwide-population-based-casecontrol-study/334704.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of this study on premature ovarian insufficiency (POI)?","Question",{"text":112,"@type":113},"The study examined how often women diagnosed with POI had earlier cancer diagnoses, and compared this frequency with age-matched controls. It also aimed to clarify the association between cancer, cancer treatments, and POI.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were cases and controls selected in the nationwide case–control design?",{"text":117,"@type":113},"Cases were all women in Finland who received hormone replacement therapy reimbursement for ovarian insufficiency before age 40 between 1988 and 2017 (n=5221). Controls were age- and municipality-matched women selected from the Finnish Population Information System (n=20822).",{"name":119,"@type":110,"acceptedAnswer":120},"When was the risk of POI highest after a cancer diagnosis?",{"text":121,"@type":113},"The risk was most pronounced during the first 2 years after a cancer diagnosis (OR 103; 95% CI 74.1 to 144). The risk also remained elevated when the time interval exceeded 10 years (OR 5.40; 95% CI 3.54 to 8.23).",{"name":123,"@type":110,"acceptedAnswer":124},"What do the results suggest about cancer survivors and POI risk?",{"text":125,"@type":113},"The findings show that 21.9% of women with POI had previously been diagnosed with cancer, corresponding to a much higher prevalence than controls. The authors conclude that cancer treatments likely play an etiological role and that POI risk should be recognized in cancer survivors for early diagnosis and intervention.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},334704,1790742549,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":46,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Received: 17 October 2023 | Revised: 14 December 2023 | Accepted: 9 January 2024  \n\n| DOI: 10. 1111/aogs.14783 |  |  |\n| --- | --- | --- |\n| OR I G I NAL R E S E AR C H ART I C L E\u003Cbr>|  | |\n| Previous cancers in women diagnosed with premature ovarian insufficiency: A nationwide population-based case–control study\u003Cbr>Heidi Silvén1,2,3  | Susanna M. Savukoski1,2,3 | Paula Pesonen4 | Riitta Niinimäki2,3,5 | Eero Pukkala6,7 | Mika Gissler8,9,10 | Eila Suvanto1,2,3 | Maarit Niinimäki1,2,3 \u003Cbr>1Department of Obstetrics and Gynecology, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, Oulu, Finland 2Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland\u003Cbr>3 Medical Research Center, University of Oulu and Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, Oulu, Finland 4Infrastructure for Population Studies, Faculty of Medicine, University of Oulu, Oulu, Finland\u003Cbr>5Department of Pediatrics, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, Oulu, Finland 6Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland\u003Cbr>7Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland 8 Department of Knowledge Brokers, THL Finnish Institute for Health and Welfare, Helsinki, Finland 9Academic Primary Health Care Center, Region Stockholm, Stockholm, Sweden\u003Cbr>10 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden |  |  |\n| Correspondence\u003Cbr>Heidi Silvén, Department of Obstetricsand Gynecology, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, 90029 Pohde, Oulu, Finland.\u003Cbr>Email: [heidi.silven@student.oulu.fi](heidi.silven@student.oulu.fi)\u003Cbr>Funding information\u003Cbr>Synnytys-ja naistentautiopintutkimussäätiö”; Juho Vainion Säätiö; Oulu Medical Research foundation; Oulun Yliopiston Tukisäätiö; the Finnish Menopause Society | \u003Cbr>Abstract\u003Cbr>Introduction: To investigate the occurrence of previous cancer diagnoses in women suffering from premature ovarian insufficiency (POI) and compare it with the general population, shedding light on the association between cancer, cancer treatments, and POI.\u003Cbr>Material and methods: We conducted a nationwide case–control study based on registry data from various sources, including the Social Insurance Institution, Finnish Population Information System, and Finnish Cancer Registry spanning from 1953 to 2018. Our participants comprised all women in Finland who, between 1988 and 2017, received hormone replacement therapy reimbursement for ovarian insufficiency before the age of 40 years (n = 5221). Controls, matched in terms of age and municipality of residence, were selected from the Finnish Population Information System (n = 20 822). Our main exposure variable was a history of cancer diagnosis preceding the diagnosis of POI. We analyzed odds ratios (OR) to compare the prevalence of previous cancersin women with POI with that in controls, stratifying results based on cancer type, age |  |\n| Abbreviations: CI, confidence interval; FCR, Finnish Cancer Registry; HRT, hormone replacement therapy; ICD-O-3, International Classification of Diseases for Oncology, third edition; OR, odds ratio; POI, premature ovarian insufficiency. |  |  |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\u003Cbr>© 2024 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetricsand Gynecology (NFOG) . |  |  |\n\n[842](842 | wileyonlinelibrary.com/journal/aogs)[ |](842 | wileyonlinelibrary.com/journal/aogs)[ wileyonlinelibrary.com/journal/aogs](842 | wileyonlinelibrary.com/journal/aogs) Acta Obstet Gynecol Scand. 2024;103:842–849 .  ","cbCaiiW7SDXWtOV5","https://ap.wps.com/l/cbCaiiW7SDXWtOV5","pdf",615209,"English","# Abstract\n## Introduction\n## Material and methods\n## Results\n## Conclusions\n## Abbreviations\n# Keywords\n# Introduction","[{\"question\":\"What was the goal of this study on premature ovarian insufficiency (POI)?\",\"answer\":\"The study examined how often women diagnosed with POI had earlier cancer diagnoses, and compared this frequency with age-matched controls. It also aimed to clarify the association between cancer, cancer treatments, and POI.\"},{\"question\":\"How were cases and controls selected in the nationwide case–control design?\",\"answer\":\"Cases were all women in Finland who received hormone replacement therapy reimbursement for ovarian insufficiency before age 40 between 1988 and 2017 (n=5221). Controls were age- and municipality-matched women selected from the Finnish Population Information System (n=20822).\"},{\"question\":\"When was the risk of POI highest after a cancer diagnosis?\",\"answer\":\"The risk was most pronounced during the first 2 years after a cancer diagnosis (OR 103; 95% CI 74.1 to 144). The risk also remained elevated when the time interval exceeded 10 years (OR 5.40; 95% CI 3.54 to 8.23).\"},{\"question\":\"What do the results suggest about cancer survivors and POI risk?\",\"answer\":\"The findings show that 21.9% of women with POI had previously been diagnosed with cancer, corresponding to a much higher prevalence than controls. The authors conclude that cancer treatments likely play an etiological role and that POI risk should be recognized in cancer survivors for early diagnosis and intervention.\"}]","Previous cancers in women diagnosed with premature ovarian insufficiency - A nationwide population-based case–control study | PDF",1790007959]